Accuryn Medical has announced that it has shipped 100,000 SmartFoley catheters across the USA.
The Accuryn SmartFoley catheter, combined with the Accuryn Monitoring system, transforms the traditional Foley catheter into a next-generation sensor to help guide acute kidney injury (AKI) care, the company says in a press release.
The system, which is now in over 70 US hospitals and being trialled in European markets, was designed to help clinicians automate clinical data, visualise trends and patterns, and act sooner to improve outcomes for patients.
“I’m proud of the work the Accuryn team has done to develop and hone the Accuryn monitoring system,” said Sanjay Banerjee, CEO of Accuryn Medical. “This sales milestone is a testament to the fact that our system not only solves a real need within critical care facilities, but also integrates seamlessly into existing workflows. We’re looking forward to growing our efforts to provide clinicians with the real-time data they need to improve care for more patients.”
Patients often experience extended hospital stays and increased costs of care due to hospital acquired infections and complications. While some of these conditions are preventable and treatable, management and diagnosis can be hindered by the time-intensive manual processes needed to monitor and assess kidney function.
The Accuryn monitoring system is setting a new standard for critical care monitoring by simplifying nurse workflow and accurately providing automated, real-time data on urine output, intra-abdominal pressure, and body temperature to enable goal-directed treatment and clinical decision support in critically ill patients.
The Accuryn SmartFoley catheter automates urine output using patented DrainLine Clearance. The Accuryn Monitor tracks urine output and detects AKI based on KDIGO [Kidney Disease Improving Global Outcomes] guidelines, hours before standard of care, which is vital for optimising treatment plans and potentially improving patient outcomes.
